Evidence map›Paper›PMID 39183387›Full record

Trial reportAmerican journal of men's health

The Effect of Botulinum Toxin (Masport) Injection Following Internal Urethrotomy of Bulbar Urethral Stricture: A Pilot Study.

Hojat Salimi, Jalil Hosseini, Rayka Sharifian, Morteza Fallah Karkan, Nasim Namiranian, Nastaran Injinari, Elham Ahmadi Basiri, Saeid Abouei, Keshvar Samadaeegelehkolaee, Alimohammad Mirjalili

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in American journal of men's health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hojat SalimiMen's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Jalil HosseiniMen's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Rayka SharifianMen's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Morteza Fallah KarkanUrology Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.ORCID 0000-0001-5166-5641
Nasim NamiranianDiabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Nastaran InjinariDiabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Elham Ahmadi BasiriTrauma and Surgery Research Center, Aja University of Medical Sciences, Tehran, Iran.
Saeid AboueiMedical Doctor, Research Committee, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Keshvar SamadaeegelehkolaeeSexual and Reproductive Health Research Center, Department of Reproductive Health and Midwifery, Faculty of Nursing and Midwifery, Mazandaran University of Medical Sciences, Sari, Iran.ORCID 0000-0002-9692-187X
Alimohammad MirjaliliReconstructive Urologist, Yazd Urology Department, Men's Health, and Reproductive Health Research Center, Yazd, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The application of Botulinum toxin (Masport) in urology has a long history. We aimed to assess the effect of local Masport on improvement in patients with urethral stricture by reducing the recurrence of urethral stricture. This pilot study conducted was a double-blind randomized clinical trial with code IRCT20191222045852N1 on patients suffering from urethral stricture. Finally, 28 patients were allocated to intervention and control groups. Twelve patients received intralesional injection with Masport in addition to internal urethrotomy, while 16 patients underwent internal urethrotomy with normal saline. The Cox regression hazard model was used to evaluate the effect of treatment status on recurrence time adjusted for the age, length, and location of the stenosis, cause of the stenosis, and history of previous operations. The effect of treatment type was significant at the .05 level. The past medical history and cause of urethral stricture had a significant impact on relapse-free survival. Also, the improvement in the mean score of the EuroQol Visual Analogue Scale (EQ-VAS), International Prostate Symptom Score (IPSS), and Q-max in the group with Masport was significantly different from the group with normal saline. The internal urethrotomy with intralesional injection of Masport has a better survival prognosis than internal urethrotomy with normal saline group. Therefore, the authors suggest that, given this successful initial clinical trial, consideration be given to future studies involving the use of botox in the management of urethral strictures in conjunction with internal urethrotomy.

Indexed as

Injections, IntralesionalUrethral StrictureAdultBotulinum Toxins, Type ADouble-Blind MethodHumansMaleMiddle AgedNeuromuscular AgentsPilot ProjectsTreatment OutcomeUrethraBotulinum Toxins, Type ANeuromuscular Agentsbotulinum toxininternal urethrotomyMasporturethral stricture

Identifiers

PMID39183387
PMCPMC11345732

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.